RODI Fertility: Revolutionizing Reproductive Medicine with Immune-Based Solutions

RODI Fertility was created to address one of the most persistent gaps in reproductive medicine: women who experience miscarriage, implantation failure, or repeated IVF failure despite “normal” findings. Led by Dr. Barbara Geladakis, RODI pioneered an immune-based approach that reframes fertility care through the lens of reproductive immunology—bringing science, clinical insight, and compassion into one protocol-driven solution.

For years, fertility care has focused primarily on hormonal, anatomical, and genetic factors. Yet a significant subset of patients continues to experience reproductive failure without a clear explanation. RODI Fertility emerged from this unmet need, built on the premise that immune mechanisms can be a decisive, yet often under-addressed, driver of infertility and pregnancy loss.After seven years of research and collaboration with scientists in the field, RODI developed its flagship innovations: RODI NK plus and RODI NK, immunomodulatory regulators designed to help recalibrate immune function and support a pregnancy-friendly environment. Unlike conventional fertility supplements that follow generic formulations, these solutions were designed around a specific clinical challenge and positioned as a practical tool for real-world use.RODI’s approach is both science-led and clinically applicable. The products are described as delivering measurable outcomes through a simple blood test, and are supported by clinical studies, peer-reviewed publications, and international visibility. With patents granted across 50 countries, RODI has established a first-in-class position in immune-mediated fertility support, helping shape a new category within reproductive care.Beyond innovation, RODI’s work is grounded in the patient experience. Miscarriage and implantation failure carry a profound emotional burden, and RODI’s mission is to offer evidence-based solutions that are not only advanced, but meaningful and accessible. As the company expands across Europe, Asia, Middle East, and beyond, it continues to set a new standard: fertility support built on research, guided by medical expertise, and driven by outcomes that matter.